IL5 and chronic obstructive pulmonary disease: A recent trial targeted eosinophilic inflammation (IL-5) to reduce exacerbation risk in eosinophilic COPD patients, suggesting that selectively eosinophilic-pathway blockers may be effective for such patients [24].